Sepsis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Sepsis – Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
- The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sepsis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
A2 Therapeutics IncA6 Pharmaceuticals LLC
ABIONYX Pharma SA
AbVacc Inc
Acepre LLC
ADEL Inc
Adrenomed AG
AiCuris Anti-infective Cures AG
AIM Vaccine Co Ltd
Aldeyra Therapeutics Inc
Allele Biotechnology and Pharmaceuticals Inc
Alphamab Oncology
Annexin Pharmaceuticals AB
Apoglyx AB
Aptahem AB
Arch Biopartners Inc
Asahi Kasei Pharma Corp
Axceso Biopharma Co Ltd
Ayuvis Research Inc
Basilea Pharmaceutica Ltd
BioAegis Therapeutics Inc
BloodCenter of Wisconsin
Brandenburg Antiinfektiva GmbH
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellics Therapeutics Inc
Cellivery Therapeutics Inc
Celloram Inc
Centers of Biomedical Research Network
Chengdu Olymvax Biopharmaceuticals Inc
Children's Hospital of Philadelphia
Chongqing Zhifei Biological Products Co Ltd
Cilian AG
Claritas Pharmaceuticals Inc
Covira Surgical Inc
Cynata Therapeutics Ltd
Deka Biosciences Inc
Dupage Medical Technology Inc
Dynomics Inc
Eight Plus One Pharmaceutical Co Ltd
Eldec Pharmaceuticals Inc
Endacea Inc
Enlivex Therapeutics Ltd
Enzychem Lifesciences Corp
Eunoia Biotech LLC
Evaxion Biotech A/S
Exoxemis Inc
Fe Pharmaceuticals Inc
Function Therapeutics Inc
Genesen Co Ltd
Genfit SA
Grand Pharmaceutical (China) Co Ltd
Grand Pharmaceutical Group Ltd
Grifols SA
Gufic BioSciences Ltd
Hibernaid Inc
HLB Science Inc
Hunan Sanqing Pharmaceutical Co Ltd
Ibex Bioscience Inc
ILIAS Biologics Inc
InflaRx NV
Issar Pharmaceuticals Pvt Ltd
JD Bioscience Inc
Jiangsu Kunli Biopharmaceutical Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
KARE Biosciences Inc
Karl-Franzens-Universitat Graz
Korea Research Institute of Bioscience and Biotechnology
Lead Discovery Center GmbH
LEAF4Life LLC
LifeArc
Marshall University
Matisse Pharmaceuticals BV
MedAbome Inc
Medical University of South Carolina
MetrioPharm AG
Microbiotix Inc
MirimGENE Co Ltd
Mochida Pharmaceutical Co Ltd
Modus Therapeutics AB
MYND Life Sciences Inc
Nanotics LLC
Northern Therapeutics Inc
Nosopharm SAS
NovaCell Technology Inc
Novartis AG
Ohio State University
Ono Pharmaceutical Co Ltd
Orbsen Therapeutics Ltd
Oryn Therapeutics
Osaka University
Paean Biotechnology Inc
Panag Pharma Inc
ProAbTech Ltd
ProThera Biologics Inc
Protheragen Inc
Purine Pharmaceuticals Inc
Pylum Biosciences Inc
Q BioMed Inc
Qrons Inc
Ra Pharmaceuticals Inc
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
Revagenix Inc
Reven Holdings Inc
RevImmune SAS
Rimonyx Pharmaceuticals Ltd
Sanofi
SATT AxLR SAS
SciClone Pharmaceuticals Holdings Ltd
Scioto Biosciences Inc
SelectImmune Pharma AB
Sentien Biotechnologies Inc
Seoul National University
SetLance srl
SFA Therapeutics Inc
Shaperon Inc
Shionogi & Co Ltd
Signablok Inc
SignPath Pharma Inc
Sorbonne University
Sulfateq BV
Summit Therapeutics Inc
Suzhou Weichao Biotechnology Co Ltd
Swedish Orphan Biovitrum AB
Synthekine Inc
Syntiron LLC
TaiRx Inc
Techfields Pharma Co Ltd
The Feinstein Institute for Medical Research
Therakind Ltd
Therapeutic Systems Research Laboratories Inc
TheraSource LLC
Tianjin Chase Sun Pharmaceutical Co Ltd
UAB Minority Health and Health Equity Research Center
University of California Riverside
University of Louisville
University of Malaya
University of Seville
US Army Medical Research & Materiel Command
ValiRx Plc
Vascular BioSciences
Weizmann Institute of Science
Wenzhou Medical University
West Lake Biomedical Technology (Hangzhou) Co Ltd
Worphmed Srl
Yabao Pharmaceutical Group Co Ltd
YNIOS Pharma srl
Zhejiang University
Zydus Lifesciences Ltd
ZZ Biotech LLC